Integrated Bulk and Single-Cell Transcriptomics Reveals the C3–C3AR1 Axis as a Candidate Mediator of Coagulome-Immune Crosstalk in Osteosarcoma
Abstract
1. Introduction
2. Materials and Methods
2.1. Public Data Acquisition
2.2. Clinical Data Acquisition
2.3. Enrichment Analysis
2.4. Score Using the Specified Gene Set
2.5. Abundance Evaluation of Immune Cells with Bulk RNA-Seq Data
2.6. Cell-Cell Communication Analysis
2.7. Prediction of Possible Transcriptional Regulatory Networks Using pySCENIC
2.8. Prediction of Prognosis by Machine Learning Method
2.9. Single Gene Pan-Cancer Analysis
2.10. Immunohistochemistry and Immunofluorescence
2.11. Statistical Analysis
3. Results
3.1. Coagulation-Related Transcriptional Characteristics Are Involved in Tumor-Promoting Pathways in OS and Can Lead to Poor Prognosis
3.2. Macrophages and Coagulation-Related Genes Play a Synergistic Role in Promoting Tumor
3.3. C3AR1 Is a Key Coagulation-Related Gene That Affects the Tumor Niche of OS
3.4. Pan-Cancer Characterization of C3AR1
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Corre, I.; Verrecchia, F.; Crenn, V.; Redini, F.; Trichet, V. The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem. Cells 2020, 9, 976. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Marcove, R.C.; Miké, V.; Hajek, J.V.; Levin, A.G.; Hutter, R.V. Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J. Bone Jt. Surg. Am. 1970, 52, 411–423. [Google Scholar] [CrossRef] [Scilit]
- Meltzer, P.S.; Helman, L.J. New Horizons in the Treatment of Osteosarcoma. N. Engl. J. Med. 2021, 385, 2066–2076. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rak, J.; Yu, J.L.; Luyendyk, J.; Mackman, N. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res. 2006, 66, 10643–10646. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Arneth, B. Coevolution of the coagulation and immune systems. Inflamm. Res. 2019, 68, 117–123. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ruf, W.; Graf, C. Coagulation signaling and cancer immunotherapy. Thromb. Res. 2020, 191, S106–S111. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Graf, C.; Wilgenbus, P.; Pagel, S.; Pott, J.; Marini, F.; Reyda, S.; Kitano, M.; Macher-Göppinger, S.; Weiler, H.; Ruf, W. Myeloid cell-synthesized coagulation factor X dampens antitumor immunity. Sci. Immunol. 2019, 4, eaaw8405. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kubala, M.H.; Punj, V.; Placencio-Hickok, V.R.; Fang, H.; Fernandez, G.E.; Sposto, R.; DeClerck, Y.A. Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer. Cell Rep. 2018, 25, 2177–2191.e7. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhang, T.; Ma, Z.; Wang, R.; Wang, Y.; Wang, S.; Cheng, Z.; Xu, H.; Jin, X.; Li, W.; Wang, X. Thrombin facilitates invasion of ovarian cancer along peritoneum by inducing monocyte differentiation toward tumor-associated macrophage-like cells. Cancer Immunol. Immunother. 2010, 59, 1097–1108. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Haist, M.; Stege, H.; Pemler, S.; Heinz, J.; Fleischer, M.I.; Graf, C.; Ruf, W.; Loquai, C.; Grabbe, S. Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study. Cancers 2021, 13, 5103. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- He, Q.; Yang, J.; Jin, Y. Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma. Brief. Bioinform. 2022, 23, bbac291. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lei, C.; Li, Y.; Yang, H.; Zhang, K.; Lu, W.; Wang, N.; Xuan, L. Unraveling breast cancer prognosis: A novel model based on coagulation-related genes. Front. Mol. Biosci. 2024, 11, 1394585. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhou, M.; Deng, Y.; Fu, Y.; Liang, R.; Liu, Y.; Liao, Q. A new prognostic model for glioblastoma multiforme based on coagulation-related genes. Transl. Cancer Res. 2023, 12, 2898–2910. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Song, B.; Chi, H.; Peng, G.; Song, Y.; Cui, Z.; Zhu, Y.; Chen, G.; Wu, J.; Liu, W.; Dong, C.; et al. Characterization of coagulation-related gene signature to predict prognosis and tumor immune microenvironment in skin cutaneous melanoma. Front. Oncol. 2022, 12, 975255. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Oshi, M.; Sarkar, J.; Tokumaru, Y.; Yan, L.; Kosaka, T.; Akiyama, H.; Nagahashi, M.; Kunisaki, C.; Endo, I.; Takabe, K. Higher intra-tumoral expression of pro-coagulation genes is a predictor of angiogenesis, epithelial mesenchymal transition and worse patient survival in gastric cancer. Am. J. Cancer Res. 2022, 12, 4001–4014. [Google Scholar] [PubMed]
- Yang, J.; Wang, C.; Zhang, Y.; Cheng, S.; Wu, M.; Gu, S.; Xu, S.; Wu, Y.; Sheng, J.; Voon, D.C.; et al. Clinical significance and immune infiltration analyses of a novel coagulation-related signature in ovarian cancer. Cancer Cell Int. 2023, 23, 232. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ma, C.; Li, R.; Yu, R.; Guo, J.; Xu, J.; Yuan, X.; Guo, J. Predictive value of preoperative platelet-to-albumin ratio and apolipoprotein B-to-apolipoprotein A1 ratio for osteosarcoma in children and adolescents: A retrospective study of 118 cases. BMC Cancer 2022, 22, 113. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zheng, L.; Qin, S.; Si, W.; Wang, A.; Xing, B.; Gao, R.; Ren, X.; Wang, L.; Wu, X.; Zhang, J.; et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 2021, 374, abe6474. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yang, Y.; Chen, X.; Pan, J.; Ning, H.; Zhang, Y.; Bo, Y.; Ren, X.; Li, J.; Qin, S.; Wang, D.; et al. Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes. Cell 2024, 187, 4790–4811.e22. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cheng, S.; Li, Z.; Gao, R.; Xing, B.; Gao, Y.; Yang, Y.; Qin, S.; Zhang, L.; Ouyang, H.; Du, P.; et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 2021, 184, 792–809.e23. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tang, F.; Li, J.; Qi, L.; Liu, D.; Bo, Y.; Qin, S.; Miao, Y.; Yu, K.; Hou, W.; Li, J.; et al. A pan-cancer single-cell panorama of human natural killer cells. Cell 2023, 186, 4235–4251.e20. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Buddingh, E.P.; Kuijjer, M.L.; Duim, R.A.; Bürger, H.; Agelopoulos, K.; Myklebost, O.; Serra, M.; Mertens, F.; Hogendoorn, P.C.; Lankester, A.C.; et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: A rationale for treatment with macrophage activating agents. Clin. Cancer Res. 2011, 17, 2110–2119. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 2020, 369, 1318–1330. [CrossRef] [Scilit] [PubMed]
- Zhou, Y.; Yang, D.; Yang, Q.; Lv, X.; Huang, W.; Zhou, Z.; Wang, Y.; Zhang, Z.; Yuan, T.; Ding, X.; et al. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat. Commun. 2020, 11, 6322. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Liu, Y.; Feng, W.; Dai, Y.; Bao, M.; Yuan, Z.; He, M.; Qin, Z.; Liao, S.; He, J.; Huang, Q.; et al. Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma. Front. Oncol. 2021, 11, 709210. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ljunggren, G.; Johansson, S.E. Use of submaximal measures of perceived exertion during bicycle ergometer exercise as predictors of maximal work capacity. J. Sports Sci. 1988, 6, 189–203. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hu, C.; Li, T.; Xu, Y.; Zhang, X.; Li, F.; Bai, J.; Chen, J.; Jiang, W.; Yang, K.; Ou, Q.; et al. CellMarker 2.0: An updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data. Nucleic Acids Res. 2023, 51, D870–D876. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Taylor, A.M.; Sheng, J.; Ng, P.K.S.; Harder, J.M.; Kumar, P.; Ahn, J.Y.; Cao, Y.; Dzis, A.M.; Jillette, N.L.; Goodspeed, A.; et al. Immunosuppressive Tumor Microenvironment of Osteosarcoma. Cancers 2025, 17, 2117. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Stelzer, G.; Rosen, N.; Plaschkes, I.; Zimmerman, S.; Twik, M.; Fishilevich, S.; Stein, T.I.; Nudel, R.; Lieder, I.; Mazor, Y.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr. Protoc. Bioinform. 2016, 54, 1.30.31–31.30.33. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ashburner, M.; Ball, C.A.; Blake, J.A.; Botstein, D.; Butler, H.; Cherry, J.M.; Davis, A.P.; Dolinski, K.; Dwight, S.S.; Eppig, J.T.; et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000, 25, 25–29. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zeng, D.; Ye, Z.; Shen, R.; Yu, G.; Wu, J.; Xiong, Y.; Zhou, R.; Qiu, W.; Huang, N.; Sun, L.; et al. IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures. Front. Immunol. 2021, 12, 687975. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jin, S.; Guerrero-Juarez, C.F.; Zhang, L.; Chang, I.; Ramos, R.; Kuan, C.H.; Myung, P.; Plikus, M.V.; Nie, Q. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 2021, 12, 1088. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Aibar, S.; González-Blas, C.B.; Moerman, T.; Huynh-Thu, V.A.; Imrichova, H.; Hulselmans, G.; Rambow, F.; Marine, J.C.; Geurts, P.; Aerts, J.; et al. SCENIC: Single-cell regulatory network inference and clustering. Nat. Methods 2017, 14, 1083–1086. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Liu, H.; Zhang, W.; Zhang, Y.; Adegboro, A.A.; Fasoranti, D.O.; Dai, L.; Pan, Z.; Liu, H.; Xiong, Y.; Li, W.; et al. Mime: A flexible machine-learning framework to construct and visualize models for clinical characteristics prediction and feature selection. Comput. Struct. Biotechnol. J. 2024, 23, 2798–2810. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Liao, C.; Wang, X. TCGAplot: An R package for integrative pan-cancer analysis and visualization of TCGA multi-omics data. BMC Bioinform. 2023, 24, 483. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Xin, P.; Xu, X.; Deng, C.; Liu, S.; Wang, Y.; Zhou, X.; Ma, H.; Wei, D.; Sun, S. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int. Immunopharmacol. 2020, 80, 106210. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to Virchow? Lancet 2001, 357, 539–545. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wen, J.H.; Li, D.Y.; Liang, S.; Yang, C.; Tang, J.X.; Liu, H.F. Macrophage autophagy in macrophage polarization, chronic inflammation and organ fibrosis. Front. Immunol. 2022, 13, 946832. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Noman, M.Z.; Hasmim, M.; Lequeux, A.; Xiao, M.; Duhem, C.; Chouaib, S.; Berchem, G.; Janji, B. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. Cells 2019, 8, 1083. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jia, Y.; Yan, Q.; Zheng, Y.; Li, L.; Zhang, B.; Chang, Z.; Wang, Z.; Tang, H.; Qin, Y.; Guan, X.Y. Long non-coding RNA NEAT1 mediated RPRD1B stability facilitates fatty acid metabolism and lymph node metastasis via c-Jun/c-Fos/SREBP1 axis in gastric cancer. J. Exp. Clin. Cancer Res. 2022, 41, 287. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wang, J.; Yu, H.; Dong, W.; Zhang, C.; Hu, M.; Ma, W.; Jiang, X.; Li, H.; Yang, P.; Xiang, D. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells’ Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways. Gastroenterology 2023, 164, 990–1005. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhou, T.; Xie, Y.; Hou, X.; Bai, W.; Li, X.; Liu, Z.; Man, Q.; Sun, J.; Fu, D.; Yan, J.; et al. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. J. Exp. Clin. Cancer Res. 2023, 42, 111. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bayleyegn, B.; Adane, T.; Getawa, S.; Aynalem, M.; Kifle, Z.D. Coagulation parameters in lung cancer patients: A systematic review and meta-analysis. J. Clin. Lab. Anal. 2022, 36, e24550. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wang, L.; Wang, J.; Li, P.; Wang, X.; Wu, S.; Shi, B. Association between short-term heart rate variability and blood coagulation in patients with breast cancer. Sci. Rep. 2021, 11, 15414. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lei, X.; Zhang, T.; Deng, Z.; Jiang, T.; Hu, Y.; Yang, N. Coagulation markers as independent predictors of prostate cancer aggressiveness: A retrospective cohort study. Sci. Rep. 2023, 13, 16073. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jiaao, L.; Wanli, G.; Kai, Z.; Feng, G.; Yunpeng, P. Coagulation parameters for the differential diagnosis of pancreatic cancer in the early stage: A retrospective study. Eur. J. Med. Res. 2023, 28, 436. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Green, D.; Karpatkin, S. Role of thrombin as a tumor growth factor. Cell Cycle 2010, 9, 656–661. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Villares, G.J.; Zigler, M.; Dobroff, A.S.; Wang, H.; Song, R.; Melnikova, V.O.; Huang, L.; Braeuer, R.R.; Bar-Eli, M. Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. Proc. Natl. Acad. Sci. USA 2011, 108, 626–631. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Adams, G.N.; Rosenfeldt, L.; Frederick, M.; Miller, W.; Waltz, D.; Kombrinck, K.; McElhinney, K.E.; Flick, M.J.; Monia, B.P.; Revenko, A.S.; et al. Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen. Cancer Res. 2015, 75, 4235–4243. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Nierodzik, M.L.; Karpatkin, S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006, 10, 355–362. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Haemmerle, M.; Stone, R.L.; Menter, D.G.; Afshar-Kharghan, V.; Sood, A.K. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 2018, 33, 965–983. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Queiroz, K.C.; Shi, K.; Duitman, J.; Aberson, H.L.; Wilmink, J.W.; van Noesel, C.J.; Richel, D.J.; Spek, C.A. Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. Int. J. Cancer 2014, 135, 2294–2304. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Delvaeye, M.; Conway, E.M. Coagulation and innate immune responses: Can we view them separately? Blood 2009, 114, 2367–2374. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Liang, H.P.; Kerschen, E.J.; Hernandez, I.; Basu, S.; Zogg, M.; Botros, F.; Jia, S.; Hessner, M.J.; Griffin, J.H.; Ruf, W.; et al. EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice. Blood 2015, 125, 2845–2854. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lawal, B.; Tseng, S.H.; Olugbodi, J.O.; Iamsaard, S.; Ilesanmi, O.B.; Mahmoud, M.H.; Ahmed, S.H.; Batiha, G.E.; Wu, A.T.H. Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance. Cancers 2021, 13, 4124. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kumar, A.; Ahmad, I.; Kanmanthareddy, A.; Gada, H. Prosthesis-Patient Mismatch Post-TAVR: A Rigid Interpretation of Something Dynamic. JACC Cardiovasc. Interv. 2024, 17, 2569. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rosberg, R.; Smolag, K.I.; Sjölund, J.; Johansson, E.; Bergelin, C.; Wahldén, J.; Pantazopoulou, V.; Ceberg, C.; Pietras, K.; Blom, A.M.; et al. Hypoxia-induced complement component 3 promotes aggressive tumor growth in the glioblastoma microenvironment. JCI Insight 2024, 9, e179854. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Magrini, E.; Di Marco, S.; Mapelli, S.N.; Perucchini, C.; Pasqualini, F.; Donato, A.; Guevara Lopez, M.L.; Carriero, R.; Ponzetta, A.; Colombo, P.; et al. Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression. Nat. Cancer 2021, 2, 218–232. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- O’Brien, R.M.; Meltzer, S.; Buckley, C.E.; Heeran, A.B.; Nugent, T.S.; Donlon, N.E.; Reynolds, J.V.; Ree, A.H.; Redalen, K.R.; Hafeez, A.; et al. Complement is increased in treatment resistant rectal cancer and modulates radioresistance. Cancer Lett. 2024, 604, 217253. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Roumenina, L.T.; Daugan, M.V.; Petitprez, F.; Sautès-Fridman, C.; Fridman, W.H. Context-dependent roles of complement in cancer. Nat. Rev. Cancer 2019, 19, 698–715. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Reis, E.S.; Mastellos, D.C.; Ricklin, D.; Mantovani, A.; Lambris, J.D. Complement in cancer: Untangling an intricate relationship. Nat. Rev. Immunol. 2018, 18, 5–18. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kleczko, E.K.; Kwak, J.W.; Schenk, E.L.; Nemenoff, R.A. Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. Front. Immunol. 2019, 10, 954. [Google Scholar] [CrossRef] [Scilit] [PubMed]






| Characteristic | Overall N = 59 | Survival N = 41 | Death N = 18 | p-Value |
|---|---|---|---|---|
| White Blood Cell Count, (×109/L) | 9.616 ± 9.037 | 9.408 ± 8.532 | 10.088 ± 10.345 | 0.576 |
| Absolute Neutrophil Count, (×109/L) | 6.817 ± 7.036 | 6.999 ± 7.248 | 6.424 ± 6.740 | 0.817 |
| Absolute Lymphocyte, (×109/L) | 1.548 ± 0.689 | 1.496 ± 0.650 | 1.669 ± 0.778 | 0.556 |
| Absolute Monocyte Count, (×109/L) | 0.603 ± 0.557 | 0.626 ± 0.572 | 0.545 ± 0.529 | 0.636 |
| Absolute Eosinophil Count, (×109/L) | 0.087 ± 0.107 | 0.098 ± 0.120 | 0.060 ± 0.059 | 0.290 |
| Absolute Basophil Count, (×109/L) | 0.057 ± 0.151 | 0.034 ± 0.027 | 0.107 ± 0.270 | 0.760 |
| Triglycerides, (mmol/L) | 1.334 ± 0.895 | 1.295 ± 0.695 | 1.428 ± 1.277 | 0.370 |
| Cholesterol, (mmol/L) | 3.898 ± 1.074 | 3.986 ± 1.179 | 3.697 ± 0.775 | 0.639 |
| HDL-C, (mmol/L) | 1.171 ± 0.374 | 1.226 ± 0.391 | 1.046 ± 0.307 | 0.152 |
| LDL-C, (mmol/L) | 2.204 ± 0.833 | 2.272 ± 0.916 | 2.049 ± 0.594 | 0.687 |
| PT, (s) | 12.076 ± 3.167 | 11.744 ± 0.951 | 12.833 ± 5.587 | 0.941 |
| INR, (ratio) | 1.017 ± 0.075 | 1.017 ± 0.080 | 1.016 ± 0.066 | 0.908 |
| aPTT, (s) | 29.125 ± 3.834 | 28.920 ± 3.607 | 29.594 ± 4.382 | 0.711 |
| TT, (s) | 18.566 ± 2.838 | 18.327 ± 3.225 | 19.111 ± 1.599 | 0.173 |
| Fibrinogen, (g/L) | 3.215 ± 0.817 | 3.085 ± 0.800 | 3.511 ± 0.800 | 0.045 |
| Gender, n (%) | 0.133 | |||
| Female | 25 (42%) | 20 (49%) | 5 (28%) | |
| Male | 34 (58%) | 21 (51%) | 13 (72%) | |
| Age, (years) | 21.305 ± 13.316 | 20.707 ± 12.528 | 22.667 ± 15.259 | 0.921 |
| Enneking stage, n (%) | 0.813 | |||
| IIA | 1 (2%) | 1 (3%) | 0 (0%) | |
| IIB | 55 (93%) | 39 (93%) | 11 (91%) | |
| III | 3 (5%) | 2 (5%) | 1 (9%) | |
| Pathological Fracture, n (%) | 6 (10%) | 3 (7.3%) | 3 (17%) | 0.415 |
| Recurrence, n (%) | 28 (47%) | 10 (24%) | 18 (100%) | <0.001 |
| Metastasis, n (%) | 6 (10%) | 1 (2.5%) | 5 (28%) | 0.044 |
| OS, (days) | 1232.712 ± 497.661 | 1414.049 ± 348.596 | 819.667 ± 546.905 | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Mu, J.; Wang, Y.; Liu, H.; He, X.; Li, Z.; Lu, M.; Tang, F.; Luo, Y.; Zhou, Y.; Min, L.; et al. Integrated Bulk and Single-Cell Transcriptomics Reveals the C3–C3AR1 Axis as a Candidate Mediator of Coagulome-Immune Crosstalk in Osteosarcoma. Biomedicines 2026, 14, 1686. https://doi.org/10.3390/biomedicines14081686
Mu J, Wang Y, Liu H, He X, Li Z, Lu M, Tang F, Luo Y, Zhou Y, Min L, et al. Integrated Bulk and Single-Cell Transcriptomics Reveals the C3–C3AR1 Axis as a Candidate Mediator of Coagulome-Immune Crosstalk in Osteosarcoma. Biomedicines. 2026; 14(8):1686. https://doi.org/10.3390/biomedicines14081686
Chicago/Turabian StyleMu, Jianhua, Yitian Wang, Han Liu, Xuanhong He, Zhuangzhuang Li, Minxun Lu, Fan Tang, Yi Luo, Yong Zhou, Li Min, and et al. 2026. "Integrated Bulk and Single-Cell Transcriptomics Reveals the C3–C3AR1 Axis as a Candidate Mediator of Coagulome-Immune Crosstalk in Osteosarcoma" Biomedicines 14, no. 8: 1686. https://doi.org/10.3390/biomedicines14081686
APA StyleMu, J., Wang, Y., Liu, H., He, X., Li, Z., Lu, M., Tang, F., Luo, Y., Zhou, Y., Min, L., & Tu, C. (2026). Integrated Bulk and Single-Cell Transcriptomics Reveals the C3–C3AR1 Axis as a Candidate Mediator of Coagulome-Immune Crosstalk in Osteosarcoma. Biomedicines, 14(8), 1686. https://doi.org/10.3390/biomedicines14081686

